1. Clinical porcine islet xenotransplantation under comprehensive regulation;Matsumoto;Transplant Proc,2014
2. U.S.Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research (CBER) Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm074354.htm
3. European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) Guideline on Xenogeneic Cell-Based Medicinal Products http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/12/WC500016936.pdf
4. Health Research Council of New Zealand Gene Technology Advisory Committee Guidelines for Preparation of Applications Involving Clinical Trials of Xenotransplantation in New Zealand http://www.hrc.govt.nz/sites/default/files/GTAC%20Guidelines%20for%20Preparation%20of%20Applications%20Involving%20Clinical%20Trials%20of%20Xenotransplantation%20in%20NZ.pdf
5. U.S.Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products: Guidance for Industry http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM359073.pdf